As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...

Cipla has opened India's first integrated lung diagnostics and wellness centre in Lajpat Nagar, Delhi. This facility offers over 60 tests f...

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...

Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...

In a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...

The company said it will continue to focus on investing towards building its speciality franchise through a combination of development with...

Cipla lost its battle with Novartis in March, when the Delhi High Court stayed the company’s request to sell copies of Novartis respiratory...

Elaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...

Sources said the court on Friday issued an interim injunction directing Cipla to stop the sale of the generic drug in the market.

Novartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent off...

Under the contract, which will run from July 2014 to April 2017, the company will supply drugs including Beclate 100, Becalate 200 and Asth...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...